Garvin A J, Simon R, Young R C, DeVita V T, Berard C W
Semin Oncol. 1980 Sep;7(3):234-43.
An essential purpose of a pathologic classification of non-Hodgkin's lymphomas is to supply guidance in the clinical management of patients. Ideally, an optimal subclassification should also be scientifically accurate, highly reproducible, and readily teachable. Such a system, when used in conjunction with uniform staging, should enable relatively homogeneous groups of patients to be defined. In the present study, we have evaluated four new systems for possible additions to the traditional Rappaport classifcation. In response to specific questions the following tentative conclusions could be drawn: (1) Within the Rappaport nodular lymphomas, there are no differences in survival between lymphomas that are totally nodular verusus those that are nodular and diffuse. (2) In lymphomas composed of small cleaved follicular center cells of the Lukes-Collins system, survival appears to be independent of pattern (follicular, follicular and diffuse, or diffuse). In contrast, in tumors classified as centroblastic-centrocytic in the Kiel classification or those classified as large cleaved or large noncleaved in the Lukes-Collins system, a totally or partially follicular pattern confers a better prognosis than its diffuse counterpart. (3) The numbers are small but there is no apparent difference in survival between cases of Rappaport's difuse well differentiated lymphocytic lymphomas with or without plasmacytoid differentiation. (4) Within the original Rappaport DPDL there were at least two distinct types of lymphomas: (1) a convoluted lymphoblastic that occurs in younger patients has a high frequency of B symptoms and carries a poor prognosis; and (2) a diffuse lymphoma that is cytologically identical to nodular PDL, occurs in older patients, and has a relatively good prognosis. In August of 1976 Rappaport modified his classification to recognize these lymphoblastic lymphomas as a distinct clinicopathologic entity. (5) In this 22-yr retrospective review, neither the Kiel nor the Lukes-Collins system could identify any relatively favorable subsets within Rappaport's category of diffuse histiocytic lymphoma. Prospective studies applying the same approach to large numbers of patients subjected to modern uniform staging and aggressive combination chemotherapy may provide data upon which to base an optimal subclassification of DHL.
非霍奇金淋巴瘤病理分类的一个基本目的是为患者的临床管理提供指导。理想情况下,一个最佳的亚分类还应在科学上准确、高度可重复且易于传授。这样一个系统,与统一分期结合使用时,应能定义相对同质的患者群体。在本研究中,我们评估了四种新系统,以确定是否可添加到传统的拉帕波特分类中。针对特定问题,可得出以下初步结论:(1)在拉帕波特结节性淋巴瘤中,完全结节性淋巴瘤与结节性和弥漫性淋巴瘤之间的生存率无差异。(2)在卢克斯-柯林斯系统中由小裂滤泡中心细胞组成的淋巴瘤中,生存率似乎与模式(滤泡性、滤泡性和弥漫性或弥漫性)无关。相比之下,在基尔分类中归类为中心母细胞-中心细胞的肿瘤或在卢克斯-柯林斯系统中归类为大裂或大无裂的肿瘤中,完全或部分滤泡性模式的预后优于弥漫性对应模式。(3)病例数量较少,但拉帕波特弥漫性高分化淋巴细胞性淋巴瘤有无浆细胞样分化的病例之间生存率无明显差异。(4)在原始的拉帕波特弥漫性高分化淋巴细胞性淋巴瘤中至少有两种不同类型的淋巴瘤:(1)一种卷曲淋巴母细胞性淋巴瘤,发生于年轻患者,B症状发生率高,预后差;(2)一种弥漫性淋巴瘤,细胞学上与结节性高分化淋巴细胞性淋巴瘤相同,发生于老年患者,预后相对较好。1976年8月,拉帕波特修改了他的分类,将这些淋巴母细胞性淋巴瘤确认为一种独特的临床病理实体。(5)在这项为期22年的回顾性研究中,基尔系统和卢克斯-柯林斯系统均未在拉帕波特弥漫性组织细胞淋巴瘤类别中识别出任何相对有利的亚组。对大量接受现代统一分期和积极联合化疗的患者采用相同方法进行前瞻性研究,可能会提供数据,为弥漫性组织细胞淋巴瘤的最佳亚分类提供依据。